Preliminary data from ongoing clinical studies suggest that DA-EPOCH-R therapy might have a superior outcome in some subtypes of DLBCL when compared to R-CHOP therapy [180, 182, 183]. The gene discussed is DDIT3; the disease is diffuse large B-cell lymphoma.